{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06922591","nct_id":"NCT06922591","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06922591. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Escalating oral doses of TNG462 in combination with oral RMC-6236","label":"Dose Escalation 1A","type":"EXPERIMENTAL"},{"description":"Escalating oral doses of TNG462 in combination with oral RMC-9805","label":"Dose escalation 1B","type":"EXPERIMENTAL"},{"description":"Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236","label":"Dose Expansion 2A","type":"EXPERIMENTAL"},{"description":"Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805","label":"Dose Expansion 2B","type":"EXPERIMENTAL"},{"description":"Escalating doses of TNG462 in combination with mFOLFIRINOX","label":"Experimental: Dose Escalation 1C","type":"EXPERIMENTAL"},{"description":"Escalating doses of TNG462 in combination with gemcitabine/nab-paclitaxel","label":"Experimental: Dose Escalation 1D","type":"EXPERIMENTAL"},{"description":"Expansion arm at the RDE(s) of TNG462 in combination with mFOLFIRINOX","label":"Experimental: Dose Expansion 2C","type":"EXPERIMENTAL"},{"description":"Expansion arm at the RDE(s) of TNG462 in combination with gemcitabine/nab-paclitaxel","label":"Experimental: Dose Expansion 2D","type":"EXPERIMENTAL"}],"collaborators":["Revolution Medicines, Inc."],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC","RAS Mutation","MTAP Deletion","Lung Cancer","Pancreatic Cancer Metastatic","Thoracic Cancer"],"enrollment":{"count":183,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TNG462","otherNames":[],"type":"DRUG"},{"name":"RMC-9805","otherNames":[],"type":"DRUG"},{"name":"RMC-6236","otherNames":[],"type":"DRUG"},{"name":"mFOLFIRINOX","otherNames":[],"type":"DRUG"},{"name":"gemcitabine/nab-paclitaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Tango Therapeutics, Inc.","official_title":"A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Maximum Tolerated Dose","timeFrame":"21 days"},{"measure":"Phase 1: Maximum Tolerated Dose","timeFrame":"28 days"},{"measure":"Phase 2: Combination Anti-neoplastic Activity","timeFrame":"12 weeks"}],"references":[],"start_date":{"date":"2025-05-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","url":"https://clinicaltrials.gov/study/NCT06922591"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06922591"}